April 15, 2013

Generic makers heralded the fiscal year 2014 budget proposed last week by the Obama administration for its embrace of generic drugs, but were critical of its provisions on patent settlements and rebates.

April 10, 2013

Legislation designed to limit the use of biosimilars has met defeat in Maryland.

April 9, 2013

The new world of targeted, specialized medicines — many of them bioengineered and many of them aimed at smaller and smaller segments of the population — isn’t just on its way. It’s here. And it’s going to radically change the practice of pharmacy.

Here’s an eye-opener: Specialty drugs will likely account for 50% of all drug costs by 2018, up from 28.7% of total prescription drug costs in 2012.

April 4, 2013

A committee of Florida's state Senate has passed a bill that could limit the use of biosimilars in the state.

April 3, 2013

According to an independent research firm, a recent pilot program to address awareness of the dangers of prescription drug abuse in teens showed 75% of all respondents were more aware of the dangers of misusing and abusing prescription drugs after participating in the educational program.

March 29, 2013

The Food and Drug Administration is seeking comment from drug makers and others concerning formal meetings between the agency and companies looking to market follow-on biologics.

March 29, 2013

A representative and a senator, both Republicans, recently introduced legislation that would repeal restrictions on health savings accounts and flexible spending accounts in the Patient Protection and Affordable Care Act of 2010 that prohibit the use of HSA and FSA account dollars for the purchase of over-the-counter drugs without a prescription.

One of the sponsors of the Family Health Care Flexibility Act, Sen. Mike Johanns of Nebraska, called the restrictions "government overreach and interference." But they're more than that: They're simply wasteful. The whole point of healthcare reform is to expand access to health care while reducing cost, and requiring an expensive and time-consuming doctor visit to get a prescription for an OTC drug fails at both goals.

March 15, 2013

The OTC industry is well-positioned to seize opportunities across the self-care space, executives at the recent Consumer Healthcare Products Association Annual Executive Conference shared with attendees. Those opportunities will be driven by greater consumer engagement and the growing realization around how much healthcare value can be drawn from expanding OTC access.

That sets the stage for some pretty favorable growth across a $38.3 billion industry. According to an Edelman in Health survey, use of over-the-counter medicines is already prevalent among Americans — almost 85% of Americans reported regular use of an OTC remedy. Convenience, efficacy and value were three of the key factors behind that prevalence, as noted in a special report compiled by DSN.

March 8, 2013

Medication-information website Drugs.com has launched a mobile app that includes access to personal medication records, drug-interaction lists and breaking health news, the company said Friday.

March 8, 2013

A new bill (HB 365) in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.

March 8, 2013

Just about every healthcare practitioner recommends over-the-counter medicines to their patients. And nearly 3-out-of-4 make that OTC recommendation as the first therapy option, according to a recent survey released by the Consumer Healthcare Products Association.

This is another proof point that OTC medicines play an important role in holding down cost.

March 6, 2013

Prescription-only pseudoephedrine laws result in well more than $278 million in additional burdens to taxpayers, according to a study published by Matrix Global Advisors.

March 6, 2013

Nearly 98% of primary care physicians, nurse practitioners and pharmacists trust and recommend over-the-counter medicines to their patients, according to a new survey released Wednesday by the Consumer Healthcare Products Association.

March 1, 2013

The Consumer Healthcare Products Association on Friday released a statement regarding a poll released last week by the Asthma and Allergy Foundation of America.

February 28, 2013

It's been long accepted that politics makes strange bedfellows. That's certainly the case with the reauthorization in 2012 of the Prescription Drug User Fee Act.

February 28, 2013

Biosimilar medicines have been approved and routinely prescribed in Europe for nearly seven years, and creation of a clear pathway for Food and Drug Administration review and approval of generic versions of bioengineered drugs was enshrined into law in the United States with the passage of the Patient Protection and Affordable Care Act nearly three years ago.

February 28, 2013

Are doctors needlessly raising the costs of America's healthcare system through their prescribing habits? Absolutely, say researchers.

February 25, 2013

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

February 22, 2013

One of the FDA's chief duties is ensuring the quality of food and drug products, and that was the focus of a keynote address delivered at the GPhA annual meeting.

February 22, 2013

Patients around the country "strongly" oppose laws that have been proposed to change popular OTC drugs to prescription-only, according to a new survey.

February 19, 2013

A new bill in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.

February 15, 2013

Two Democrats from West Virginia are sponsoring legislation in the House and Senate to combat prescription drug abuse.

February 8, 2013

Biotech drug maker Amgen plans to launch six biosimilar drugs starting in 2017, according to published reports.

February 8, 2013

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately.

With growth in traditional pharmaceuticals expected to slow down significantly, a growing number of drug makers — branded and generic alike — see specialty drugs as their main sources of revenue for the foreseeable future. At the same time, those drug makers not invested in specialty may be looking for growth opportunities in consumer health.